Elderly Patients (>65 Years)

3

Review clinical trials related to Elderly Patients (>65 Years). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.

Participants needed: 300
Trial details
Age: 65+Biological sex: AllType: ObservationalSponsor: Chiara LanzaniUpdated: Aug 13, 2025Locations: 1Duration: 6 Months
Eligibility criteria

Participant is willing and able to give informed consent for participation in th... [+5]

Current or previous use of SGLT2i; [+1]

Status: Recruiting

Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC

The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a multicenter, randomized controlled clinical trial. The main question it aims to answer is: the combination of electroacupuncture and PD-1 inhibitor therapy has demonstrated significant improvements in both clinical efficacy and safety profiles among elderly patients with advanced NSCLC. Researchers will compare a sham electroacupuncture group combined with PD-1 inhibitor therapy (serving as the control group) to see if the intervention group exhibits superior therapeutic efficacy and safety outcomes. Participants will be randomly assigned to one of two groups: an electroacupuncture combined with an immune checkpoint inhibitor group, or a sham electroacupuncture combined with an immune checkpoint inhibitor group. The immune checkpoint inhibitor will be administered on a 21-day cycle, with a total of 4 to 6 treatment cycles, followed by the option for maintenance therapy. Electroacupuncture treatment will commence on the same day as the initiation of the immune checkpoint inhibitor cycle, administered once daily for a total of five sessions per cycle, with 4 to 6 cycles in total. The primary outcome measure is progression-free survival (PFS). Secondary outcomes include objective response rate (ORR), quality of life, immune function, traditional Chinese medicine syndrome scores for lung cancer, and safety parameters. This study aims to establish the efficacy and safety of electroacupuncture combined with PD-1 inhibitors in elderly patients with advanced NSCLC. Additionally, peripheral non-coding RNA will be collected at baseline to analyze differentially expressed genes, thereby identifying molecular predictive biomarkers for patients who may benefit most from this combined treatment approach.

Participants needed: 120
Trial details
Age: 65-100Biological sex: AllType: InterventionalSponsor: Kong FanmingUpdated: Jul 25, 2025Locations: 1
Eligibility criteria

Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) confirmed by hist... [+6]

Patients with a history of or concurrent other malignancies within the past 5 ye... [+6]

Status: Not yet recruiting

Low- vs. Normal-Flow Anesthesia and Delirium After Hip Fracture in the Elderly

The aim of this study is to investigate the relationship between low-flow and normal-flow anesthesia techniques and the development of postoperative delirium in elderly patients undergoing surgery for hip fracture.

Participants needed: 128
Trial details
Age: 65+Biological sex: AllType: ObservationalSponsor: Gaziosmanpasa Research and Education HospitalUpdated: May 15, 2025
Eligibility criteria

Not listed